Proteome Systems and High Q expand program for Huntington's disease biomarkers

16-Nov-2004

Proteome Systems and the High Q Foundation announced the expansion of a biomarker discovery program for Huntington's disease (HD). The program is seeking to discover biomarkers that will be used for monitoring the onset and progression of HD and provide insights into the efficacy of existing and future treatments.

In the pilot program commenced in April 2004, Proteome Systems identified changes in protein expression in a small set of Huntington's patients. The expanded 18 month program will apply proprietary targeted approaches to identify new biomarkers for the disease. The intention is to develop clinical tests to assist in monitoring the onset and progression of the disease.

Proteome Systems will receive technology access fees and milestone payments under the 18 month program, up to a maximum of US$3 million.

"We are delighted that the outcomes from the pilot program have demonstrated our capacity to discover biomarkers for HD. Our state of the art technology, combined with High Q's expertise and knowledge of HD, gives us a good chance of delivering tests that can assist in patient care and quality of life for HD sufferers" said Dr. Jenny Harry, Head of Discovery at Proteome Systems.

Dr. Allan Tobin, Senior Scientific Advisor to the High Q Foundation, said "Proteome Systems has proven that its Discovery researchers have made concrete progress on this HD biomarker program. We are excited to expand the relationship with Proteome Systems and anticipate the discovery of biomarkers that will enable us to track the course and treatment of HD."

https://www.bionity.com/en/news/40840/proteome-systems-and-high-q-expand-program-for-huntington-s-disease-biomarkers.html